FUNDERMA (Fundación Nacional de Dermatología), Santa Cruz, Bolivia.
Servicio Departamental de Salud, Departamento de La Paz, La Paz, Bolivia.
Am J Trop Med Hyg. 2018 Nov;99(5):1153-1155. doi: 10.4269/ajtmh.18-0183.
Bolivian cutaneous leishmaniasis due to was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 μg/mm lesion area on days 1, 3, and 5). Ninety-two per cent of 50 patients cured. Comparison to historic controls at our site suggests that the efficacy of the two drugs was additive. Adverse effects and cost were also additive. This combination may be attractive when a prime consideration is efficacy (e.g., in rescue therapy), avoidance of parenteral therapy, or the desire to treat locally and also provide systemic protection against parasite dissemination.
玻利维亚皮肤利什曼病由 引起，采用米替福新（150mg/天，连用 28 天）联合皮内注射戊双脒（第 1、3、5 天，每个皮损 120μg）治疗。50 例患者中 92%治愈。与本单位历史对照相比，两种药物的疗效呈相加作用。不良反应和费用也呈相加作用。当首要考虑因素是疗效（例如，补救治疗）、避免采用注射治疗，或希望局部治疗并提供全身保护以防止寄生虫传播时，这种联合用药可能具有吸引力。
